InvestorRoom | Kitov Pharmaceuticals TyrNovo to Present at BIO-Europe SpringĀ® 2018 Conference Treatment with TyrNovo's NT219 in combination with targeted cancer drugs, as well as chemotherapy and immuno-oncology therapies, prevented acquired resistance and reversed resistance of colon, lung and head-and-neck cancers in patient-derived xenograft models Thu, 08 Mar 2018 09:33:00 -0500 Kitov Announces Consensiā„¢ as Brand Name for KIT-302 Thu, 14 Dec 2017 09:44:00 -0500 Kitov Pharmaceuticals Announces Receipt of FDA's Favorable Response to NT219's pre-IND Meeting Package TyrNovo to Initiate Clinical Development on Advanced Pancreatic Cancer Patients Wed, 01 Nov 2017 09:15:00 -0400 Kitov Pharmaceuticals Announces Phase III/IV Clinical Trial for KIT-302 Successfully Meets Primary Endpoint, and also Demonstrates Drug Candidate Improves Renal Function Thu, 26 Oct 2017 14:00:00 -0400 Kitov Boosts Ownership in TyrNovo and Oncology Platform Through Exchange of Shares for Stock - Kitov acquires an additional 27% ownership stake in TyrNovo and NT219, its oncology therapeutic candidate, in exchange for Kitov stock at a value of $2.50 per ADS. Fri, 06 Oct 2017 08:20:00 -0400